GT Biopharma (NASDAQ:GTBP) Stock Rating Lowered by Wall Street Zen

GT Biopharma (NASDAQ:GTBP) was downgraded by research analysts at Wall Street Zen to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GT Biopharma presently has a consensus rating of “Sell”.

GT Biopharma Price Performance

Shares of GTBP opened at $8.61 on Friday. The company has a market capitalization of $15.50 million, a PE ratio of -0.06 and a beta of 0.91. The company’s fifty day moving average price is $8.02 and its 200 day moving average price is $9.66. GT Biopharma has a one year low of $4.91 and a one year high of $34.25.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Friday, August 14th. The company reported ($3.00) EPS for the quarter, missing analysts’ consensus estimates of ($2.00) by ($1.00). Analysts anticipate that GT Biopharma will post -10.75 earnings per share for the current year.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. Everhart Financial Group Inc. acquired a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 100,000 shares of the company’s stock, valued at approximately $49,000. Everhart Financial Group Inc. owned 0.23% of GT Biopharma as of its most recent filing with the Securities & Exchange Commission. 8.15% of the stock is owned by hedge funds and other institutional investors.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).